Josephine M. Egan

Endocrinology, Diabetes and Metabolism · 2008–2010

A researcher in the Science corpus: 2 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Josephine M. Egan trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Jens J. Holst
  2. M. Nauck
  3. D. J. Drucker

Papers from Josephine M. Egan's perspective

Ordered by how strongly the researchers Josephine M. Egan trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. (Diabetes Care)
  2. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. (Diabetes Care)
  3. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. (Journal of Clinical Endocrinology and Metabolism)
  4. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. (Journal of Cardiac Failure)
  5. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 (Nature Medicine)
  6. Mechanisms of action of glucagon-like peptide 1 in the pancreas. (Pharmacology and Therapeutics)
  7. Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1 (Proceedings of the National Academy of Sciences of the United States of America)
  8. The physiology of glucagon-like peptide 1. (Physiological Reviews)
  9. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. (American Journal of Physiology. Endocrinology and Metabolism)
  10. Inhibition of gastric inhibitory polypeptide signaling prevents obesity (Nature Medicine)

Their papers